Novo Nordisk and Hims & Hers Partner to Expand Access to GLP-1 Treatments
Novo Nordisk and Hims & Hers are partnering to widen access to branded GLP-1 treatments, shifting demand away from compounded products. What it means for compounders and clinical sponsors.
FDA Inspection Trends Highlight Ongoing Quality System Weaknesses
Recent comments from an FDA investigator point to the same recurring Form 483 themes: quality unit oversight, procedures not followed, and investigations that do not close the loop.